What was the market valuation of the China neuropathic pain market in 2024?

The market valuation was $585.0 Million in 2024. Read More

What is the projected market valuation for the China neuropathic pain market by 2035?

The projected valuation for 2035 is $1406.0 Million. Read More

What is the expected CAGR for the China neuropathic pain market during the forecast period 2025 - 2035?

The expected CAGR is 8.3% during the forecast period 2025 - 2035. Read More

Which segment had the highest valuation in the treatment type category in 2024?

In 2024, the medications segment had the highest valuation at $292.5 Million. Read More

What are the projected values for diabetic neuropathy in 2035?

The projected value for diabetic neuropathy in 2035 is $420.0 Million. Read More

Which route of administration is expected to have the highest valuation by 2035?

The injectable route is expected to have the highest valuation at $576.0 Million by 2035. Read More

What was the valuation of the chemotherapy-induced peripheral neuropathy segment in 2024?

The valuation for chemotherapy-induced peripheral neuropathy in 2024 was $174.5 Million. Read More

How does the valuation of hospitals as an end user compare to clinics in 2035?

By 2035, hospitals are projected to have a valuation of $703.0 Million, significantly higher than clinics at $280.0 Million. Read More

Which key player is associated with the China neuropathic pain market?

Key players include Pfizer Inc, Johnson & Johnson, and Eli Lilly and Company, among others. Read More

What is the projected growth trend for the postherpetic neuralgia segment by 2035?

The postherpetic neuralgia segment is projected to grow to $350.0 Million by 2035. Read More

China Neuropathic Pain Market

ID: MRFR/HC/47674-HCR

200 Pages

Nidhi Mandole

Last Updated: April 06, 2026

China Neuropathic Pain Market Research Report By Type of Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Trigeminal Neuralgia, Chemotherapy-Induced Peripheral Neuropathy), By Treatment Type (Medications, Physical Therapy, Surgical Procedures, Electrical Stimulation), By Route of Administration (Oral, Topical, Injectable) and By End User (Hospitals, Clinics, Home Care) - Growth & Industry Forecast 2025 To 2035

China Neuropathic Pain Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type of Neuropathic Pain (USD Million)
  1. 4.1.1 Diabetic Neuropathy
  2. 4.1.2 Postherpetic Neuralgia
  3. 4.1.3 Trigeminal Neuralgia
  4. 4.1.4 Chemotherapy-Induced Peripheral Neuropathy
2. 4.2 Construction, BY Treatment Type (USD Million)
  1. 4.2.1 Medications
  2. 4.2.2 Physical Therapy
  3. 4.2.3 Surgical Procedures
  4. 4.2.4 Electrical Stimulation
3. 4.3 Construction, BY Route of Administration (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Topical
  3. 4.3.3 Injectable
4. 4.4 Construction, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinics
  3. 4.4.3 Home Care
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Johnson & Johnson (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Astellas Pharma Inc (JP)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly and Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie Inc (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GSK plc (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN
3. 6.3 CHINA MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 CHINA MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE OF NEUROPATHIC PAIN, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE OF NEUROPATHIC PAIN, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY END USER, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Construction Market Segmentation

Construction By Type of Neuropathic Pain (USD Million, 2025-2035)

Diabetic Neuropathy
Postherpetic Neuralgia
Trigeminal Neuralgia
Chemotherapy-Induced Peripheral Neuropathy

Construction By Treatment Type (USD Million, 2025-2035)

Medications
Physical Therapy
Surgical Procedures
Electrical Stimulation

Construction By Route of Administration (USD Million, 2025-2035)

Oral
Topical
Injectable

Construction By End User (USD Million, 2025-2035)

Hospitals
Clinics
Home Care

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”